Almost all the anti-VEGF therapeutic approaches present are monoclonal antibodies directly targeting one or more mature isoforms of VEGF in serum, or VEGF receptors, thereby inhibiting tumor growth [18,38]. The gene discussed is VEGFA; the disease is neoplasm.